COSTAR
Disease site: Head and Neck
Treatment Modality: Radiotherapy
Status: Open to recruitment
COSTAR is a phase III multi-centre randomised controlled trial designed to demonstrate a difference in the proportion of patients suffering sensori-neural hearing loss of at least 10dB in bone conduction at 4000 Hz, as assessed by an audiogram done 12 months post radiotherapy, in patients treated with cochlea-sparing IMRT and conventional radiotherapy.
The work is supported by the NCRI CTrad Group and the NCRI Head and Neck Cancer Studies Group.
Chief Investigator: | Dr Chris Nutting |
Sponsor: | The Royal Marsden NHS Foundation Trust |
Source of funding: | Cancer Research UK |
ISRCTN: | 81772291 |
In the Clinical Trials Section
